{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:30:47Z","timestamp":1793417447425,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9\u201327.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3\u201321.4) and those without prescriptions (19.6%, 95% CI: 18.1\u201321.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-026-02159-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:41:26Z","timestamp":1784569286000},"page":"2164-2171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-6310","authenticated-orcid":false,"given":"Claudia R.","family":"Villatoro Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector D.","family":"Estrada Tock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5050-4974","authenticated-orcid":false,"given":"Haoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura N.","family":"McEwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kraftson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.soard.2024.01.012","volume":"20","author":"B Clapp","year":"2024","unstructured":"Clapp B, Ponce J, Corbett J, Ghanem OM, Kurian M, Rogers AM, et al. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2024;20:425\u201331.","journal-title":"Surg Obes Relat Dis"},{"key":"2159_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.17476\/jmbs.2023.12.2.76","volume":"12","author":"JC Kim","year":"2023","unstructured":"Kim JC, Kim M-G, Park JK, Lee S, Kim J, Cho YS, et al. Outcomes and adverse events after bariatric surgery: an updated systematic review and meta-analysis, 2013\u20132023. J Metab Bariatr Surg. 2023;12:76\u201388.","journal-title":"J Metab Bariatr Surg"},{"key":"2159_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","volume":"377","author":"TD Adams","year":"2017","unstructured":"Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377:1143\u201355.","journal-title":"N Engl J Med"},{"key":"2159_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2024.0318","volume":"331","author":"AP Courcoulas","year":"2024","unstructured":"Courcoulas AP, Patti ME, Hu B, Arterburn DE, Simonson DC, Gourash WF, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024;331:654\u201364.","journal-title":"JAMA"},{"key":"2159_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s11695-025-07743-6","volume":"35","author":"PB Bregion","year":"2025","unstructured":"Bregion PB, Reis AM, Juc\u00e1 RH, de Oliveira-Filho JR, da Rocha Soares GA, Cazzo E, et al. Patients with severe obesity undergoing Roux-En-Y gastric bypass versus sleeve gastrectomy: a systematic review and an updated meta-analysis. Obes Surg. 2025;35:1146\u201359.","journal-title":"Obes Surg"},{"key":"2159_CR6","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1007\/s00464-022-09785-8","volume":"37","author":"EO Akpinar","year":"2023","unstructured":"Akpinar EO, Liem RSL, Nienhuijs SW, Greve JWM, Marang-van de Mheen PJ. Dutch Audit for treatment of obesity research group. weight recurrence after sleeve gastrectomy versus Roux-en-Y gastric bypass: a propensity score matched nationwide analysis. Surg Endosc. 2023;37:4351\u20139.","journal-title":"Surg Endosc"},{"key":"2159_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.soard.2020.03.034","volume":"16","author":"WC King","year":"2020","unstructured":"King WC, Hinerman AS, Courcoulas AP. Weight regain after bariatric surgery: a systematic literature review and comparison across studies using a large reference sample. Surg Obes Relat Dis. 2020;16:1133\u201344.","journal-title":"Surg Obes Relat Dis"},{"key":"2159_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s40519-022-01403-9","volume":"27","author":"F Muratori","year":"2022","unstructured":"Muratori F, Vignati F, Di Sacco G, Gavazzi L, Pellegrino D, Del Prete M. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord. 2022;27:2775\u201381.","journal-title":"Eat Weight Disord"},{"key":"2159_CR9","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s11695-018-3393-7","volume":"28","author":"P Rye","year":"2018","unstructured":"Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28:3553\u20138.","journal-title":"Obes Surg"},{"key":"2159_CR10","doi-asserted-by":"crossref","unstructured":"Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9:e12323.","DOI":"10.1111\/cob.12323"},{"key":"2159_CR11","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1007\/s11695-021-05535-2","volume":"31","author":"MA Rubio","year":"2021","unstructured":"Rubio MA, Ramos-Lev\u00ed AM. Initial experience with alternate-day liraglutide for weight regain following bariatric surgery. Obes Surg. 2021;31:4216\u20138.","journal-title":"Obes Surg"},{"key":"2159_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","volume":"74","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125\u201339.","journal-title":"Annu Rev Med"},{"key":"2159_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s11695-024-07181-w","volume":"34","author":"SA Firkins","year":"2024","unstructured":"Firkins SA, Chittajallu V, Flora B, Yoo H, Simons-Linares R. Utilization of anti-obesity medications after bariatric surgery: analysis of a large national database. Obes Surg. 2024;34:1415\u201324.","journal-title":"Obes Surg"},{"key":"2159_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1586\/14779072.2015.1054810","volume":"13","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13:753\u201367.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2159_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","volume":"25","author":"NC Bergmann","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023;25:18\u201335.","journal-title":"Diabetes Obes Metab"},{"key":"2159_CR16","unstructured":"Lilly. Trulicity Cost Information. [WWW document]. URL https:\/\/pricinginfo.lilly.com\/trulicity 2025."},{"key":"2159_CR17","unstructured":"Lilly. Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions. [WWW document]. URL https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-offer-all-approved-doses-zepbound-tirzepatide-single-dose 2025."},{"key":"2159_CR18","unstructured":"N. Nordisk. Novo Care. [WWW document]. URL https:\/\/www.novocare.com\/obesity\/products\/wegovy\/get-product.html 2025."},{"key":"2159_CR19","first-page":"335","volume":"7","author":"AM Walker","year":"1996","unstructured":"Walker AM. Confounding by indication. Epidemiology. 1996;7:335\u20136.","journal-title":"Epidemiology"},{"key":"2159_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamasurg.2025.0001","volume":"160","author":"V Mathur","year":"2025","unstructured":"Mathur V, Wasden K, Shin TH, Medhati P, Nimeri AA, Tavakkoli A, et al. Neoadjuvant semaglutide, bariatric surgery weight loss, and overall outcomes. JAMA Surg. 2025;160:594\u20136.","journal-title":"JAMA Surg"},{"key":"2159_CR21","doi-asserted-by":"crossref","unstructured":"\u00c7al\u0131k Ba\u015faran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. Int J Obes 2024;49:412\u201317.","DOI":"10.1038\/s41366-024-01461-2"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02159-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:04:26Z","timestamp":1793415866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02159-3","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CVS, HET, HT, and LNM report no conflicts of interest. AK has received honoraria as co-organizer for the Obesity Summit in Michigan. AER holds leadership positions and has received travel honoraria from the Obesity Society, the American Board of Obesity Medicine Board of Directors, and the Endocrine Society. She is a part-time employee of Rewind and has received grant support from Boehringer Ingelheim. WHH serves on data safety monitoring boards for Merck Sharp & Dohme and Rivus Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}